Early economic evaluation of emerging health technologies: protocol of a systematic review by Ba’ Pham et al.
Pham et al. Systematic Reviews 2014, 3:81
http://www.systematicreviewsjournal.com/content/3/1/81PROTOCOL Open AccessEarly economic evaluation of emerging health
technologies: protocol of a systematic review
Ba’ Pham1,2*, Hong Anh Thi Tu2, Dolly Han2, Petros Pechlivanoglou1, Fiona Miller1,2, Valeria Rac1,2, Warren Chin3,
Andrea C Tricco4, Mike Paulden1,5, Joanna Bielecki1 and Murray Krahn1,2,6Abstract
Background: The concept of early health technology assessment, discussed well over a decade, has now been
collaboratively implemented by industry, government, and academia to select and expedite the development of emerging
technologies that may address the needs of patients and health systems. Early economic evaluation is essential to assess
the value of emerging technologies, but empirical data to inform the current practice of early evaluation is limited. We
propose a systematic review of early economic evaluation studies in order to better understand the current practice.
Methods/design: This protocol describes a systematic review of economic evaluation studies of regulated health
technologies in which the evaluation is conducted prior to regulatory approval and when the technology effectiveness is
not well established. Included studies must report an economic evaluation, defined as the comparative analysis of
alternatives with respect to their associated costs and health consequences, and must evaluate some regulated health
technology such as pharmaceuticals, biologics, high-risk medical devices, or biomarkers. We will conduct the literature
search on multiple databases, including MEDLINE, EMBASE, the Centre for Reviews and Dissemination Databases, and
EconLit. Additional citations will be identified via scanning reference lists and author searching. We suspect that
many early economic evaluation studies are unpublished, especially those conducted for internal use only.
Additionally, we use a chain-referral sampling approach to identify authors of unpublished studies who work
in technology discovery and development, starting out with our contact lists and authors who published relevant
studies. Citation screening and full-text review will be conducted by pairs of reviewers. Abstracted data will include
those related to the decision context and decision problem of the early evaluation, evaluation methods (e.g., data
sources, methods, and assumptions used to identify, measure, and value the likely effectiveness and the costs and
consequences of the new technology, handling of uncertainty), and whether the study results adequately address
the main study question or objective. Data will be summarized overall and stratified by publication status.
Discussion: This study is timely to inform early economic evaluation practice, given the international trend in early
health technology assessment initiatives.Background
Economic evaluation is the comparative analysis of alter-
native technologies with respect to their costs and con-
sequences [1]. It is often used late in the evaluation of
drugs, devices, and other technologies to inform cover-
age decisions [2]. This is problematic because the evi-
dence portfolio at the time of the reimbursement* Correspondence: ba.pham@theta.utoronto.ca
1Toronto Health Economics and Technology Assessment Collaborative,
University of Toronto, Leslie Dan Pharmacy Building, 6th floor, Room 651,
144 College Street, Toronto, Ontario M5S 3M2, Canada
2Institute of Health Policy, Management and Evaluation, University of
Toronto, 155 College St, Toronto, Ontario M5S 3M2, Canada
Full list of author information is available at the end of the article
© 2014 Pham et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the ordecision is often incomplete. Cost and preference data
are often not gathered prospectively within clinical trials
designed to evaluate effectiveness. This means that ana-
lysts cannot directly use trial data and must struggle to
assemble evidence from a variety of sources and settings
to evaluate the cost-effectiveness of new interventions
[3]. Published data suggest that considerable economic
uncertainty existed in about half of the submissions for
reimbursement decisions [4]. Also, clinical trial design is
rarely informed by ex ante economic modeling. This
means that optimal strategies and the full range of sub-
groups may not have been fully considered prior to com-
mencing the clinical research program.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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of technology evaluation. As an example, Vallejo-Torres
et al. illustrate a three-stage cost-effectiveness analysis of
a new medical device: an early phase in which simple
methods are used to estimate the maximum price attain-
able for the technology, a mid-stage which synthesizes
data into a cost-effective model and identifies which in-
formation is most valuable to reduce decision uncer-
tainty, and a late stage in which all relevant information
is synthesized [5]. The results suggest that early and it-
erative economic evaluation could be useful to inform
decisions along the technology development process.
Early evaluation can contribute to decision-making by
both industry and government [6,7]. From an industry's
perspective, early evaluation may be used for early mar-
ket assessment, managing research and development
portfolios, and informing pricing and reimbursement
scenarios. From the policy perspective, decision makers
may benefit from information supplied by early evalu-
ation. Thus, there is interest from both innovators and
payers in early health technology assessment and, more
specifically, early economic evaluation, to inform plan-
ning and development decisions by industry and to in-
form the potential of new technologies that may meet
health system needs [8].
Though interest in early economic evaluation is con-
siderable, much applied research is still at the pilot stage.
There is uncertainty about which technologies can bene-
fit from early evaluation, what methods are appropriate,
and the contribution of early economic evaluation to
health technology assessment [8]. The aim of this sys-
tematic review is to describe the characteristics of early
economic evaluation of emerging technologies and to
understand current methods to early evaluation.
Methods/design
This protocol describes a systematic review of economic
evaluation studies that are conducted to inform the de-
velopment and planning of early evaluation of emerging
health technologies.
Inclusion criteria
An economic evaluation is defined as the comparative
analysis of alternatives with respect to their associated
costs and health consequences. A study is included if it
reports an early economic evaluation of a regulated
health technology in order to inform the development of
the technology (e.g., pre-clinical research or phase I or II
studies). For this review, regulated health technologies
include pharmaceuticals, biologics, medical devices, or
biomarkers. The term ‘biologic’ refers to a class of thera-
peutics that are produced by means of biological pro-
cesses, including, for example, the blood production-
stimulating protein erythropoietin, a growth-stimulatinghormone, a gene therapy, a monoclonal antibody, or a
vaccine [9]. The term ‘medical device’ refers to a class II
device (e.g., blood pressure monitors, contact lenses,
pregnancy test kits, single-use surgical instruments,
catheters), a class III device (e.g., ventilators, cardiac
monitors, hip implants, knee implants, lasers, chlamydia
test kits, glucose meters), or a class IV device (e.g., defi-
brillators, pacemakers, coronary stents, HIV test kits,
neurosurgical shunts) that requires product licensing for
general marketing purposes (examples are from a pres-
entation by Ms. Sarah Chandler of Health Canada to
MaRS-Excite, September 2012, with permission). The
term ‘biomarker’ (or a biological marker) refers to an ob-
jectively measured and evaluated indicator of a normal
biological process, a pathogenic process (e.g., a DNA se-
quence that is associated with susceptibility to disease),
or a pharmacologic response to a therapeutic interven-
tion [10].
Literature search
The literature search will be conducted on multiple da-
tabases, including MEDLINE (Ovid), MEDLINE In-
Process (Ovid), EMBASE (Ovid), the Centre for Reviews
and Dissemination: National Health Services Economic
Evaluation Database (NHS EED), the Cochrane Library:
Health Technology Assessment Database (HTA Data-
base), and EconLit. The first four sources are standard
repositories of economic evaluation studies. The last
database is a reliable source of citations and abstracts of
economic research [11]. All databases will be searched
from the date of inception until present.
The search used both Medical Subject Headings
(MeSH) as well as keyword variants of all relevant terms,
including keyword terms derived from MeSH scope
notes to increase retrieval of citations from Medline In-
Process. The search developed in MEDLINE will be
adopted with the syntax and subject headings appropri-
ate for the other databases mentioned. In addition to
early economic evaluation keywords and MeSH terms
generated through scoping search (below), the final
search strategy will include the validated NHS EED
search filter and a published MEDLINE G and EMBASE
G filter to identify potentially relevant citations of eco-
nomic evaluation studies in MEDLINE and EMBASE
[12]. Both MEDLINE G and EMBASE G filters were
tested and showed that they improve the search preci-
sion [12]; however, both have been modified to conform
to this study's needs. Namely, the subject heading for
randomized control studies (RCTs) was removed from
original filters, since we did not want to limit the re-
trieved studies only to RCTs. Limits that are part of
NHS EED, MEDLINE G, and EMBASE G filters in-
cluded humans and publication type. The final search
was not limited by language.
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well defined and it is not included in the MeSH con-
trolled vocabulary, an initial scoping search was per-
formed in order to identify potential candidate keyword
terms as well as MeSH subject headings. A set of seed
articles was used to develop the MeSH terms and key-
words used in the literature search [2,5-8,13-22]. These
articles were selected because they are commonly cited
and highly relevant to early health technology assess-
ment or early economic evaluation. The relevant MeSHTable 1 Aspects of early economic evaluation and associated
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ORterms harvested from the seed articles include ‘device
approval,’ ‘diffusion of innovation,’ and ‘decision support
techniques.’
From the seed articles, we extracted the cited key-
words and other keywords that are deemed relevant to
the aspects of early economic evaluation. Table 1 de-
scribes these aspects and the associated keywords. The
first aspect is that the evaluation is conducted at an early
phase in the development of the emerging technology.
The objective of an early evaluation is to examine thekeywords used in the literature search
ywords
e$ OR potential).tw. adj2 (effect$ OR safety OR cost-effect$ OR efficiency
impact).tw.
droom.tw. OR (effect$ adj2 gap).tw.
rl$ OR iterative$ OR continu$ OR ongoing OR ‘on-going’ OR dynamic$
ex$ante OR pre$develop$ OR constructive).tw. adj3 (econom$ OR
alth econom$’ OR pharmacoeconom$ OR analys$ OR evaluation OR
e$ OR approach$ OR assessment$ OR Bayesian OR ‘health technology
essment’ OR ‘technology assessment’).tw.
velopment-accompanying’.tw.
rly$stage’ OR earl$).tw. adj2 decision?.tw.
iority adj2 set?).tw. OR decision.tw adj2 (gate$ OR point$).tw.
oduct$ adj2 development$).tw. OR (polic$ adj2 development$).tw.
-licens$’ OR ‘in licens$’ OR inlicens$).tw.
ly in research’.tw. OR ‘only with research’.tw. OR ‘in the context of
earch’.tw. OR (cover$ adj2 evidence).tw.
terim OR condition$ OR ((dependent OR dependant OR contingent) adj
on OR on)) OR restrict$) adj2 (fund$ OR financed OR reimburse$ OR
er$ OR approv$ OR list$ OR access$ OR licens$ OR licenc$)).tw. OR
ndition$ of coverage$’.tw. OR ‘condition$ of reimburse$’.tw. OR (pricing
commercialization).tw.
vestment? or marketing or promot$ or progress$ or advancement) adj2
cision$ or incentive$ or inducement$ or uncertaint$ or incertitude$ or
nomic$)).tw.
no-go’.tw. OR ‘go no go’.tw. OR ‘go\no-go’.tw. OR ‘go\no go’.tw. OR
\ no-go’.tw. OR ‘go \ no go’.tw.
rl$ OR scarc$ OR limit$ OR gap$ OR spars$ OR circumscrib$) adj2
ta OR evidence)).tw.
l adj2 (evidence OR data) adj3 (unavailable OR available OR exist)
hase II’ or ‘phase I’ or ‘phase 1’ or ‘phase 2’) adj2 trial$).tw.(phase adj
or ‘I’ or ‘II’ or ‘2’ or ‘IIa’ or ‘2a’)).tw.
idence$) adj2 development$).tw.
search and development’ OR ‘R&D’).tw.
rl$ or mid$ or develop$ or formative$ or determinative$ or decisiv$ or
ign$ or concept$ or investigation$) adj2 (phase? or process$ or stage?
‘life cycle’ or ‘lifecycle’ or cycle?)).tw.
erging OR earl$ OR pilot OR pre$develop$ OR new$ OR novel OR
cent OR original OR groundbreaking OR ‘ground-breaking’ OR pioneer$
‘cutting-edge’ OR ‘cutting edge’ OR ‘leading-edge’ OR ‘leading edge’ OR
ical$ OR trailblaz$ OR trendset$ OR seminal$ OR innovati$ or
convention$ OR innovate$ OR emergent OR constructive OR promising
developing OR ‘recently introduced’) adj3 (technolog$ OR drug? OR
atment? OR intervention? OR pharmaceutical? OR device? OR diagnos$
screen$ OR therapeutic$ OR implement$ OR development? OR service)).tw.
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ation is to provide decision support for product and pol-
icy development. There is limited supporting evidence
regarding the effectiveness of the technology. Lastly,
early evaluation may have an influence on the design
and future performance of the technology.
The search strategy has been developed by an informa-
tion analyst with the review team and will be peer-
reviewed by another information analyst from a systematic
review research group [23]. Peer-reviewing of the litera-
ture search strategy will be conducted according to the
Peer Review of Electronic Search Strategies (PRESS)
statement [24]. The protocol for this systematic review
is registered at PROSPERO, the International prospect-
ive register of systematic reviews (registration number
CRD42013004636) [25].
Additional citations will be identified via scanning the
reference lists, author searching of potentially relevant
studies, and forward citation searching in Scopus. We
suspect that many early economic evaluation studies are
unpublished, especially those conducted by industry for
internal use only. There appears to be no straightforward
way to identify authors of these unpublished studies. We
will therefore consider a chain-referral sampling ap-
proach to sample ‘hidden populations’ in our attempt to
contact these authors [26].
In the chain-referral sampling approach, a hidden
population is one in which a sampling frame (i.e., a list
of all the members of the population) cannot be con-
structed in advance. As an alternative, new members
are selected from the social network of existing mem-
bers of the sample. In this approach, first a number of
seeds are selected [26]. These seeds are members of
the hidden population that have been identified: au-
thors of published early economic evaluation studies
who work for industry, and similar individuals identi-
fied from our contact files. The seeds are contacted
and form the first stage (stage 0) of the sampling process.
The seeds identify other members of the population. The
members identified in the next stage (stage 1) are
approached and then asked to identify other members.
This process is continued until no new members could
be identified.
We fully recognize that the above sampling scheme may
not yield a comprehensive collection of unpublished study
reports. The key barrier to access to internal reports of
early evaluation may be the reluctance to share proprietary
information. Possible authors will be contacted by email.
We will follow up by phone with authors who contributed
to unpublished studies in order to discuss their involve-
ment and, if possible, request information about the un-
published material. For this approach, non-responders are
defined as a lack of response after three attempts to con-
tact a member of the sampling population.Study selection
Due to the broad inclusion criteria, screening of poten-
tially relevant citations will be conducted by pairs of re-
viewers who are formally trained and experienced in
economic evaluation. Full-text reports of citations that
are deemed relevant by one screener will be obtained.
Reasons for exclusion will be captured for studies that
are deemed to be not relevant for the review. Full-text
review will be conducted in pairs; disagreement will be
discussed and, if necessary, adjudicated by another
health economist.
Data abstraction
Table 2 describes data elements that are going to be ex-
tracted from the included studies. First, understanding
the decision context is necessary to discern the contribu-
tion of early evaluation to decision-making in product
and policy development. Data pertaining to the decision
context will be abstracted (e.g., who initiates the evalu-
ation, who commissions it, the funding sources, why an
evaluation is needed right now, who conducts the evalu-
ation, and the primary target audience). Other abstracted
data include the decision problem, disease classification,
and target population, technology type (e.g., pharmaceuti-
cals, medical devices, biomarkers), and technology stage
(e.g., pre-clinical, phase I or II studies). Data pertaining to
the methodological aspects of an early evaluation will be
abstracted, especially how authors of included studies han-
dled uncertainty in the early evaluation (e.g., probabilistic
sensitivity analysis, value of information analysis).
Open text coding will be used to capture the following
descriptions: the likely effectiveness of a new technology
and how the associated health consequences and re-
sources used were measured and valued. These descrip-
tions will be used to discern the data sources, methods,
and assumptions involved in the early evaluation. We
will assess as to whether the results of an included study
are adequate to answer the main study questions or ob-
jective, according to authors of included studies and ac-
cording to the reviewers. A pair of reviewers using the
Dedoose software for qualitative literature review will
abstract each included study independently [31].
Evidence synthesis
Characteristics of early economic evaluation studies will
be summarized according to the various aspects that de-
fine early evaluation (Table 2). Given the qualitative na-
ture of this systematic review, there will be no quantitative
evidence synthesis. Unpublished studies obtained from
the chain-referral sampling will be summarized separately
because the representativeness of this sample of unpub-
lished studies (relative to the population of early economic
evaluation conducted to support internal decisions) is
uncertain.
Table 2 Abstracted data from included studies
Values Source
Decision context
Who initiate the evaluation? For example, policy decision makers, industryb, third-party payers, hospital managers/
administrators, clinicians, patients or patient advocacy groups, not reported
[27]
Who commissioned it? For example, policy decision makers, industryb, third-party payers, hospital managers/
administrators, clinicians, patients or patient advocacy groups, not reported
[27]
What are the funding sources of the study? For example, public, private, both, others, not reported [27]
Why is an evaluation needed right now? Informing product development, informing policies, not reported [27]
Who conducted the study? For example, academia, public, private, multiple sources, others, not reported [27]
Primary target audience according to the
decision context
For example, policy decision makers, industryb, third-party payers, hospital managers/
administrators, clinicians, patients or patient advocacy groups, not reported
[27]
Defining the decision problem
Decision problem Open coding. Decision problems will be classified. For example, the primary reason for
initiating the early evaluation could be product development, health policy
[28,29]
Disease or clinical problem ICD-10 major categories (see listing in footnotes) [30]
Target population For example, patients, at-risk individuals, general public, unclear [29]
Health technology
Technology type For example, pharmaceuticals, medical devices, diagnostic devices, other therapeutic technologies [28]
Technology stage For example, basic, translational research, clinical researchc [8]
Methodological aspects of the EE
Perspective For example, societal, publicly funded health-care system, third-party payers
(e.g., insurance companies), not reported
[28,29]
Type of evaluations For example, CEA, CUA, CMA, CBA, others [28,29]
Basis of the evaluation For example, trial-based, model-based, prospective or retrospective analysis, others [29]
Time horizon Numerical number, not reported [28,29]
Adjusted for differential timing? Numerical percentage, not reported [28,29]
Likely effect of the new technology
Quantification of the likely effecta Open coding to identify data sources, methods, assumptionsd [28,29]
Valuing health outcomes
Valuation of the likely effecta Open coding to identify data sources, methods, assumptionsd [28,29]
Resources used and costs
Quantification of the likely impact on resourcesa Open coding to identify data sources, methods, assumptionsd [28,29]
Modeling, if appropriate
Model type For example, decision tree, state transition (e.g., Markov), discrete event simulation,
dynamic transition model, others
[28,29]
Handling of variability and uncertainty
Scenario analysis (e.g., structural uncertainty) Yes, no [28,29]
Sensitivity analysis (e.g., one-way, multiple-way) Yes, no [28,29]
Probabilistic sensitivity analysis Yes, no [28,29]
Value-of-information analysis Yes, no [28,29]
Presenting results of the economic evaluation
According to the authors, are results likely to be
influential to the decision problem?
Yes, no, unclear [28,29]
According to the reviewers, are results likely to
be influential to the decision problem?
Yes, no, unclear [28,29]
aDefinition of treatment effect of a technology can be summarized as the difference between the duration and state of health or HRQL (including the impact of any adverse
effects of treatment) that would be experienced on average by patients receiving the technology and that experienced by the same group were they to receive alternative care;
bindustry would include pharmaceutical, device, or genomic manufacturers; investors or inventors;ctechnologies are ready for diffusion after regulatory approval, certification of
laboratory quality, or marketing authorization; dtext coding and review of text descriptions across included studies to derive a broad classification for data sources (e.g., expert
opinion, individual patient data, administrative databases, clinical registries), methods used (e.g., systematic review, meta-analysis, RCT, non-RCT) and types of assumptions
(e.g., based upon basic science, early clinical experience). CEA cost-effectiveness analysis, CUA cost-utility analysis, CMA cost-minimization analysis, CBA cost-benefit analysis, QALY
quality-adjusted life years, HRQOL health-related quality of life, ICER incremental cost-effectiveness ratio, CE cost-effectiveness, PSA probabilistic sensitivity analysis.
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This protocol describes a systematic review of published
and unpublished studies of early economic evaluation of
regulated health technologies, when the supporting evi-
dence for their effectiveness is not fully established. The
aim is to understand current practice regarding the use
of early economic evaluation to inform decisions in the
development of emerging technologies, including deci-
sions regarding the allocation of private and public re-
sources for the development of these technologies and
decisions regarding the planning and design of research
programs to collect additional evidence to support regu-
latory and reimbursement requirements. This systematic
review will summarize the methods used in early eco-
nomic evaluation and provide data regarding the contri-
bution of early economic evaluation to decision-making
for product and policy development.
Our systematic review is timely. Conceptual discussion
of early HTA over a decade ago has evolved into con-
crete implementations over recent years [6,21,32-34]. As
we understand it, early HTA initiatives now exist in the
UK, the Netherlands, Austria, and Ontario [35,36,21,37].
These initiatives facilitate the collaboration between pri-
vate enterprises, public sectors, and academia in the de-
velopment of selective technologies that address the
needs of patients and health systems and, to varied ex-
tent, investment expectations [35]. Early economic evi-
dence may facilitate decisions regarding the selection of
promising technologies and the complex trade-offs be-
tween public and private investments [36].
Economic evaluation is essential for health technology
assessment. Ijzerman and colleagues review previous
work and methods of early health technology assessment
and propose a conceptual framework for early assess-
ment that acknowledges the different phases in technol-
ogy development and the specific decision problems
faced by different decision makers [8]. They review a
range of tools to identify and evaluate technologies in
development, most notably early health economic mod-
eling. They suggest that early HTA is an emerging field
of research that will likely become more important be-
cause of the increasingly complex trade-offs between in-
vestments and access in medical product development.
The method outlined in this protocol is sometimes re-
ferred to as a meta-epidemiological investigation. In par-
ticular, there are well-established precedence regarding
the use of systematic review to investigate factors affect-
ing the conduct and reporting of trials, systematic re-
views, and economic evaluations of health interventions
[38-45]. By adapting a systematic approach to our inves-
tigation, our aim is to collect relevant data from a repre-
sentative sample of all early economic evaluation studies
and, therefore, reliably discern the contribution of early
economic evaluation to product and policy development.Competing interests
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